Merck Provides Update on P-III (KEYNOTE-689) Study of Keytruda as a Perioperative Treatment of Head and Neck Squamous Cell Carcinoma
Shots:
- The P-III (KEYNOTE-689) study is assessing Keytruda as neoadj., followed by Keyruda with SoC radiotherapy (±cisplatin) as adj. & then as maintenance in newly diagnosed, resected locally advanced HNSCC (stage III or IVA) patients (n=704)
- The pre-specified interim analysis depicted a significantly improved EFS (1EP) & mPR (2EP), with a safety profile aligning with the previous established results in the ITT population
- Furthermore, a trend favoring improved OS was observed but it was not significant at this interim analysis among patients with PD-L1 CPS ≥10 tumors. OS assessment will continue in the next analysis, with data to be highlighted at future conferences & submitted to regulatory authorities
Ref: Merck | Image: Merck
Related News:- ABL Bio Collaborates with Merck to Develop ABL103 Plus Keytruda for Treating Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
